Domov › Rakovina pľúc › Massachusetts › Boston
Klinické štúdie Rakovina pľúc v meste Boston, MA
62 štúdií pre Rakovina pľúc hľadá účastníkov v zariadeniach v meste Boston a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Prebieha nábor
- Dana-Farber Cancer Institute, Boston
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Prebieha náborFáza 3
- Tufts Medical Center, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Prebieha náborFáza 3
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
Prebieha náborFáza 1
- PHN-012-001 Site, Boston
A Registry for People With Lung Cancer
Prebieha náborObservačná štúdia
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Prebieha náborFáza 2/3
- Dana-Farber Cancer Institute, Boston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Prebieha náborFáza 2
- Research Site, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Prebieha náborFáza 2/3
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Prebieha náborFáza 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Prebieha náborFáza 1
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Prebieha náborFáza 1/2
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Prebieha náborFáza 1
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Prebieha náborFáza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Massachusetts General Hospital, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Prebieha náborFáza 3
- Boston Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Prebieha náborFáza 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
Prebieha náborObservačná štúdia
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
Prebieha náborObservačná štúdia
- Massachusetts General Hospital, Boston
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
Prebieha nábor
- Brigham and Women's Hospital, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Massachusetts General Hospital Cancer Center, Boston
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
Prebieha nábor
- Dana-Farber Cancer Institute, Boston
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
Prebieha nábor
- Dana-Farber Cancer Institute, Boston
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Prebieha náborVítaní zdravých dobrovoľníkov
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Prebieha náborFáza 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
Prebieha nábor
- Massachusetts General Hospital, Boston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
Prebieha náborObservačná štúdia
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Prebieha náborFáza 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Prediction Augmented Screening Initiative
Prebieha nábor
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Prebieha náborFáza 1
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Prebieha náborFáza 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
Prebieha nábor
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Avecure Flexible Microwave Ablation Probe For Lung Nodules
Prebieha nábor
- Beth Israel Deaconess Medical Center, Boston
A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
Prebieha nábor
- Massachusetts General Hospital, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Prebieha náborFáza 1/2
- Dana-Farber Cancer Institute, Boston
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
Prebieha náborVítaní zdravých dobrovoľníkov
- Massachusetts General Hospital (MGH) / Harvard, Boston
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Prebieha náborVítaní zdravých dobrovoľníkov
- Brigham and Womens Hospital, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Prebieha náborFáza 2
- Massachusetts General Hospital, Boston
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Prebieha náborFáza 1Vítaní zdravých dobrovoľníkov
- Massachusetts General Hospital, Boston
Lung Cancer Screening in High-risk Black Individuals
Prebieha náborVítaní zdravých dobrovoľníkov
- Massachusetts General Hospital Cancer Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Prebieha nábor
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Prebieha nábor
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Image Guided VATS vs. VATS Resection
Prebieha nábor
- Brigham and Women's Hospital, Boston
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
Prebieha náborObservačná štúdia
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
Prebieha náborVítaní zdravých dobrovoľníkov
- Dana Farber Cancer Institute, Boston
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Molecular and Genetic Analysis of Lung Cancer
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Massachusetts General Hospital, Boston
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
Prebieha náborObservačná štúdia
- Boston University Medical Center, Boston
Štúdie Rakovina pľúc v iných mestách
- Houston, TX78 štúdií
- New York City, NY60 štúdií
- Los Angeles, CA45 štúdií
- Washington, DC41 štúdií
- Arlington, VA41 štúdií
- Chicago, IL41 štúdií
- Nashville, TN40 štúdií
- Baltimore, MD40 štúdií
- St. Louis, MO39 štúdií
- Columbus, OH37 štúdií
- Philadelphia, PA36 štúdií
- Seattle, WA33 štúdií
Iné štúdie v Boston
- Rakovina prsníka111 štúdií
- Nemalobunkový karcinóm pľúc90 štúdií
- Rakovina (všetky typy)86 štúdií
- Kolorektálny karcinóm63 štúdií
- Metastatická rakovina63 štúdií
- Rakovina vaječníkov61 štúdií
- Rakovina prostaty59 štúdií
- Depresia52 štúdií
- Rakovina endometria50 štúdií
- Srdcové zlyhanie44 štúdií
- Akútna myeloidná leukémia44 štúdií
- Rakovina pankreasu43 štúdií
Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.